These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610 [TBL] [Abstract][Full Text] [Related]
4. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757 [TBL] [Abstract][Full Text] [Related]
11. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046 [TBL] [Abstract][Full Text] [Related]
12. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Ridolfi L; Ridolfi R Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Burke EE; Zager JS Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682 [TBL] [Abstract][Full Text] [Related]
14. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452 [TBL] [Abstract][Full Text] [Related]
15. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
16. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Shah DJ; Dronca RS Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873 [TBL] [Abstract][Full Text] [Related]
17. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145 [TBL] [Abstract][Full Text] [Related]
19. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262 [TBL] [Abstract][Full Text] [Related]
20. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? Warner AB; Postow MA Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]